Description
A3 Cell Line | CL-0315 | Gentaur US, UK & Europe Disrtribition
Media: CM-0315
Organism: Homo sapiens, Human
Application: N/A
Background: The Jurkat cells were treated with Fas Antibody and isolated by limiting dilution to obtain a cell line that had a low spontaneous rate of resistance to Fas-medicated apoptosis. The resulting wild-type A3 subclone is very sensitive to Fas-mediated apoptosis. Wild-type A3 cells were made neomycin resistant and treated with three cycles of exposure to the frameshifting mutagen ICR-191 to isolate clones harboring recessive mutations that were resistant to killing by Fas antibody. ICR-191 treated clones were serially diluted in 96-well plates in the presence of Fas Antibody for 3 to 5 weeks. Two of these ICR-191 treated clones have been deposited at the ATCC. They are I 9. 2, a clone with a mutation in the cysteine protease caspase-8/FLICE and I 2. 1, a clone with a mutation in the adaptor FADD.
Age: N/A
Tissue: Peripheral blood
Morphology: Lymphoblast
Growth Properties: Suspension
Doubling Time: N/A
Biosafty: 1
Medium: RPMI-1640(PM150110)+10% FBS+1% P/S(PB180120)
Subculturing: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2×10^5 viable cells/ml. Maintain cell density between 1×10^5 and 1×10^6 viable cells/ml.
Ratio: 1:2 to 1:4
Renewal: Every 2 to 3 days
Cryopreservation: Freeze medium: 60% Basal medium+30% FBS+10% DMSO Storage temperature: Liquid nitrogen vapor phase
Culture Conditions: Atmosphere: Air, 95%; CO2, 5% Temperature: 37℃
Effects: N/A
Duration: N/A
Lead Time: 3-5 days
